on one or more of all arrays. The correction strategy yields a valid statistical test, while the replacement strategy with IQS ≥ 0.9 eliminates most spurious associations. Both strategies maintain statistical power.
Introduction
Genotype imputation methods are widely used to extend the utility of genome-wide association studies (GWAS). Genotype imputation is powerful because it can potentially identify causal single nucleotide polymorphisms (SNPs) that are not genotyped in the study data and can provide higher resolution for associated regions. However, bias can exist if research subjects are genotyped on different genotyping arrays. There are two main sources of biases in this situation. For SNPs which are not available on all arrays, genotypes are measured for some individuals but imputed for others. Measured genotypes are more accurately determined, while imputed genotypes possess some uncertainty, which leads to the bias. In addition, different genotyping arrays can give rise to differential imputation errors due to different sets of input SNP genotypes. For instance, genotyping arrays with denser SNP coverage generally result in greater imputation ac-
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Genome-wide association studies · Imputation · Spurious associations · Genotyping arrays Abstract Genotype imputation is a powerful approach in genomewide association studies (GWAS) because it can provide higher resolution for associated regions and facilitate metaanalysis. However, bias can exist if different genotyping arrays are used and are unbalanced for case versus control subjects. The intersection imputation strategy [imputation based on single nucleotide polymorphisms (SNPs) available on all arrays] is a valid strategy that eliminates the bias caused by unbalanced genotyping, but achieved at the expense of reduced statistical power. In order to improve power in this situation, we introduce two new strategies: the replacement strategy based on the imputation quality score (IQS) ≥ 0.9 and the correction strategy. The IQS is a score that we have previously introduced based on Cohen's kappa of rater agreement. The replacement strategy with IQS ≥ 0.9 is a hybrid approach that utilizes measured genotypes for SNPs available on one or more of all arrays whenever the SNP has a high imputation quality (defined by IQS ≥ 0.9). The correction strategy combines measured genotypes as well as imputed and corrected genotype dosages for SNPs available curacy compared to arrays with sparser coverage. Several studies have shown that imputation errors may bring about biases and spurious associations, and filtering SNPs based on their imputation quality or accuracy before performing association tests cannot eliminate all the false positives [1] [2] [3] .
If an equal number of cases and controls are genotyped on each array, then the bias introduced by different genotyping arrays applies equally to cases and controls, and may not lead to spurious associations. This emphasizes the importance of the study design. At times, researchers have to use different arrays due to budget constraints or the availability of denser genotyping arrays. In those situations, they should try their best to ensure that the same number of cases and controls are genotyped on the same array to minimize false-positive rates. However, this requirement is not always met, especially when genotype data are combined from several studies. If case and control subjects are severely unbalanced on each genotyping array, meta-analysis is not a favorable approach due to the low power. However, if we simply combine the genotypes from different arrays, spurious associations due to imputation are likely to occur. Two strategies of imputation across genotyping arrays are possible: (1) imputation based on the union of genotyped SNPs (i.e., SNPs available on at least one of all arrays) [2] , and (2) imputation based on the intersection of genotyped SNPs (i.e., SNPs available on all arrays) [1] . However, both strategies have their weaknesses. The union strategy results in spurious associations in the absence of a genotyping bias and is not a valid approach [1] . The intersection strategy does not introduce spurious associations [1] , but it results in a reduced statistical power due to leaving out some of the available genotyping data.
We devised two new strategies: the replacement strategy based on the imputation quality score (IQS) ≥ 0.9 and the correction strategy. Both strategies reduce spurious associations compared to the union strategy and improve statistical power compared to the intersection strategy, thus offering valid and powerful approaches for analyzing unbalanced case-control genotyping data.
Materials and Methods

Genotype Data
We utilized genotype data from subjects in the Collaborative Genetic Study of Nicotine Dependence (COGEND). The subjects' genotypes were generated using the Illumina 1M array, as part of the Study of Addiction: Genetics and Environment (SAGE; dbGaP accession No. phs000092.v1.p1, release date September 23, 2008), or using the Illumina HumanOmni2.5 array, as part of the Gene Environment Association Studies-2 (GENEVA2) initiative 2 (dbGaP accession No. phs000404.v1.p1, release date July 26, 2011). For subjects genotyped in both SAGE and GENEVA2, GENEVA2 genotypes were chosen because more SNPs were available on the Omni2.5 array. Related subjects, identified from combining the SAGE and GENEVA2 subjects, were removed. We analyzed 1,952 European American (EA) subjects remained in COGEND (1,026 subjects from SAGE and 926 subjects from GENEVA2) after we excluded 9 subjects with a missing rate >3% and used the genotype data from chromosome 22. After excluding the SNPs with a missing rate >3% and SNPs which deviate from Hardy-Weinberg equilibrium, there were 32,903 chromosome 22 SNPs on the Illumina Omni2.5 array and 14,071 chromosome 22 SNPs on the Illumina 1M array available. 9,601 SNPs with the same chromosome positions in SAGE (1M) and GENEVA2 (Omni2.5) composed the set of intersection SNPs. We imputed 411,376 SNPs based on the intersection SNPs with reference to the 1000 Genomes Project.
Phenotype Data
Nicotine dependence is a common psychiatric disorder. The Fagerström Test for Nicotine Dependence (FTND) [4] is widely used to determine the severity of nicotine dependence. In our study, subjects with FTND scores ≥ 4 were considered to be cases, and control subjects had FTND scores = 0 or 1. In total, 152 cases, 868 controls and 6 individuals with missing phenotypes were genotyped on the Illumina 1M array. There were 841 cases and 85 controls who were genotyped on the Illumina Omni2.5 array. In total, there were 993 cases, 953 controls and 6 subjects with missing phenotypes in our study. Imputation IMPUTE2 [5, 6] was selected as it offers optimal performance over other imputation methods based on the prior evaluation in African Americans (AAs) with reference to the 1000 Genomes reference panels released in February 2012 [7] . Subjects in COGEND were imputed with reference to the 1000 Genomes ALL released in April 2012 (also known as 'cosmopolitan' panel), starting with the SNPs that were present on both arrays. As a first step prior to imputation, SNP checks were implemented to evaluate whether the minor allele in COGEND EAs was the same as the minor allele in the 1000 Genomes reference panel EUR. Imputation was preceded with pre-phasing of whole chromosomes using SHAPEIT2 (see http://www.shapeit.fr/) as recommended by the IMPUTE2 developers to improve imputation accuracy and speed computational time [8] . Pre-phased haplotypes were then imputed using IM-PUTE2 with 5-MB chunks and 1-MB flanking regions, except in instances where the chunked size is expanded due to there being a small number of genotyped SNPs (for example, centromeric and telomeric regions). A SNP filtering option was implemented in IMPUTE2 to remove SNPs that were monomorphic in both AFR and EUR panels based on the prior evaluation of imputation performance in AAs [7] . In addition, the indels were removed from the dataset. SNPs with quality_info <0.3 were filtered out ('quality_info' is an internal imputation quality metric of IMPUTE2 and the cutoff of 0.3 is commonly used for post-imputation SNP filtering.) The imputation was performed once, and all strategies tested in this paper shared the same genotyping and imputation data. 
Imputation Quality Score
The IQS is a score that we have previously introduced based on Cohen's kappa of rater agreement [9] . It adjusts for chance agreement between imputed and experimentally determined genotypes. We demonstrated that IQS values can provide evidence for whether a SNP is imputed well for other subjects from common imputations [9] . Figure 1 illustrates the four strategies we tested. Group 1 represents the subjects who were genotyped on the Illumina 1M array, while Group 2 consists of the subjects genotyped on the Illumina Omni2.5 array. The SNPs tested in the association analysis were classified into four zones. SNPs available on both arrays are in Zone A. Zone B contains SNPs only available on the Illumina 1M The difference between this strategy and the intersection strategy is that we replaced the imputed genotypes of Group 2 with their measured genotypes for SNPs in Zone C. We applied the replacement strategy for SNPs available only on the Omni2.5 array, not for SNPs available only on the 1M array: only 31.8% of SNPs on the 1M array are not on the Omni2.5 array, thus the replacement for SNPs in Zone B has little impact on the falsepositive rate. For all strategies tested in this paper, the differences are restricted to SNPs in Zone C. One of our devised strategies is the replacement strategy with IQS ≥ 0.9, as shown in figure 1 c. A high IQS indicates a high imputation quality, which means the imputed genotypes are close to the true genotypes. In other words, we can use measured genotypes for some individuals while using imputed genotypes for others only when the IQS of this SNP is high. Thus, we chose IQS ≥ 0.9 as the threshold for replacement. For SNPs having IQS <0.9, we used imputed genotypes for both groups and avoided bias by treating Group 1 and Group 2 the same. For SNPs with IQS ≥ 0.9, we used imputed genotypes for Group 1 and measured genotypes for Group 2. In this way, we used available genotyping data when the imputation was of comparable accuracy to maximize data quality. We expected that this strategy would improve power since we made use of more available genotyping data. In order to save researchers from the trouble of IQS calculation as well as dividing the SNPs into two categories according to their IQS, we propose another strategy, the correction strategy, which is shown in figure 1 d. We used measured genotypes of Group 2 but imputed and corrected genotypes of Group 1 for SNPs in Zone C. We expected that the correction of imputed dosages would make it closer to the true genotypes than the original dosages, thus increasing statistical power.
Different Strategies
Imputed Dosage Correction
In order to correct imputed dosages, we classified and summarized the true and imputed genotypes of subjects who were both genotyped and imputed (individuals in Group 2 for SNPs in Zone C). Table 1 shows the marginal cross-classification of the genotypes, which can also be used to compute IQS [9] . From 
Simulation
Phenotype Simulation Subjects genotyped on the Illumina Omni2.5 array were assigned as 'cases' and individuals genotyped on the Illumina 1M array were assigned as 'controls'. There were 23 subjects who were genotyped using both arrays; their phenotypes were assigned to 'missing'. In this way, we simulated the situation that cases and controls are genotyped on different arrays. Meta-analysis cannot be performed in this case and we are going to evaluate the statistical power of the strategies using the simulated data. For simulations, there were 903 cases, 1,026 controls and 23 subjects having missing phenotypes.
Genotype Simulation
We used the multiplicative model to construct diseases with different prevalences (K = 0.01, 0.1, 0.2), and the odds ratio (OR) was set to 1. . For each disease model, we simulated 1,000 times in order to calculate power by the percentage of 1,000 replicates that achieved a p value <3.06 × 10 -6 , which is adjusted from the standard genome-wide significance level of 5 × 10 -8 [10] by dividing the length proportion of chromosome 22 in the whole genome.
We calculated disease penetrance functions based on disease prevalence (K), OR and allele frequencies. The formulas are as following: 
Based on the assigned case-control status and the above conditional probabilities, we simulated the true genotypes at the causal locus for all subjects. For the 1,000 replicates, genotypes of the subjects may change based on the conditional probabilities of each genotype given the phenotype. Then, we sampled the imputed dosage for each individual according to measured genotype versus imputed genotype (both are real data) on the Illumina Omni2.5 array.
Association Analysis
The SNP association analyses were conducted using PLINK (see http://pngu.mgh.harvard.edu/ ∼ purcell/plink/dosage.shtml) [11] . By adding the '-dosage' option, the uncertainty of the imputed genotypes was taken into account.
Results
False-Positive Rates
Q-Q plots compare the observed p value distribution with the expected p value distribution and provide a visual impression of the bias in association tests. Since true association signals only comprise a small percentage of tested SNPs, a large deviation of the observed p value distribution from the expected distribution indicates a large number of false-positive signals and the existence of bias. In addition, we reported the number of SNPs with p values <3.06 × 10 -6 . The intersection strategy is a good approach to eliminate false-positive signals which are due to differential imputation errors, as shown in figure 2 a. There are no significant SNPs with p values <3.06 × 10 -6 . However, this strategy does not make use of experimentally determined genotype data for SNPs that are present only on one array. Instead, genotypes of all individuals for those SNPs are imputed based on SNPs available on both arrays.
In order to better take advantage of all available data, we replaced the imputed genotype dosages of subjects genotyped on the Omni2.5 array with their measured genotypes for SNPs only on the Omni2.5 array. This replacement without any threshold led to a dramatic increase of spurious associations, as shown in figure 2 b. A total of 277 false positives exist with this strategy.
Comparing the above two strategies, the bias should come from the different ways of determining the genotypes of study subjects for the same SNP. For the replacement strategy without any threshold, the genotypes of some subjects were more accurately determined through direct genotyping, while others were imperfectly determined through imputation. To reduce this bias, we set a threshold for imputation quality and considered the replacement strategy with 'exp_freq_a1 ≥ 0.01' and 'quality_info ≥ 0.9'. 'exp_freq_a1' and 'quality_info' are internal quality metrics of IMPUTE2 (see http://mathgen. stats.ox.ac.uk/impute/impute_v2.html#info_metric_de-tails). SNPs that were only present on the Omni2.5 array and met these two criteria were thought to be imputed well and replaced with their experimentally determined genotypes. However, the false-positive rates remained high (153 SNPs having p values <3.06 × 10 -6 ), as shown in figure 2 c.
The IQS is an effective statistic to distinguish poorlyimputed and well-imputed SNPs [9] . We proposed a replacement approach that utilizes the experimentally determined genotypes for SNPs present only on one array whenever the SNP has a high imputation quality, characterized by IQS ≥ 0.9. This strategy eliminated most falsepositive signals and only 2 spurious associations remained, as shown in figure 2 d.This replacement strategy with IQS ≥ 0.9 is a major improvement compared to the above two replacement strategies.
To overcome the limitations of IQS, we devised the correction strategy as an improvement over the replacement strategy without threshold. We used the measured genotypes of individuals genotyped on the Omni2.5 array for SNPs only available on the Omni2.5 chip, but genotypes of subjects from the 1M array were imputed and then corrected. The detailed method of the imputed dosage correction has been explained in Materials and Methods. 78 placement strategy with IQS ≥ 0.9 eliminated most of the false positives (2 spurious associations remained). We then constructed disease models with different prevalences (see section Simulation) and compared the increase in power of the two new strategies to the intersection strategy. Power was calculated by the percentage of 1,000 replicates which obtained a p value <3.06 × 10 -6 . Table 2 shows the power of the three strategies when OR was set to 1.3. For different prevalences and different MAFs of the causal SNP, the replacement strategy with IQS ≥ 0.9 and the correction strategy both increased the power compared to the intersection strategy. For example, when we simulated rs1873233 (IQS = 0.9071 and MAF = 0.197) to be the causal SNP of a disease with a prevalence of 0.1, the power of the replacement strategy with IQS ≥ 0.9 increased from 11.2 to 32.0% and the power of the correction strategy increased from 11.2 to 19.0%. SNP rs362150 (IQS = 0.9998) served as a control since its In order to test whether these two strategies have biases, we set OR to 1.0 and did the simulation again. We calculated the percentage of 1,000 replicates that obtained a p value no more than 0.05, as shown in table 3 . The mean p values of 1,000 replicates are shown in the online supplementary material. Most of the percentages were around 5%, which demonstrates that these two new strategies had little bias and the increase of power was not a reflection of false positives. In addition, we calculated the percentages for the replacement strategy with respect to causal SNPs with IQS <0.9; results are shown in parentheses in table 3 . For rs6005267 and rs7284681, the percentages were 9.0 and 11.3%, respectively. This big deviation from 5% indicated that the threshold of IQS ≥ 0.9 was necessary for the replacement strategy. 
Discussion
Genotype imputation is a widely used approach in GWAS, and many studies have evaluated strategies to increase the imputation quality and accuracy and thus improve the power of GWAS. The HapMap Project and the 1000 Genomes Project are the two main sources of reference panels for imputation. The 1000 Genomes reference panels provide a larger number of variants than the HapMap panels with comparable imputation accuracy for variants that are available in both reference panels [7, 12] . An advantage of using the 1000 Genomes reference data is the opportunity to identify rare and low-frequency variants [12] . The 1000 Genomes ALL panel ('cosmopolitan' panel) is best for imputing admixed populations in preliminary studies. After that, follow-up studies with respect to significant or suggestive SNPs present in more closely related populations are recommended [7] . Among the three commonly used imputation software packages (IMPUTE2, BEAGLE and MACH), IMPUTE2 was selected in our study because it generally achieves the highest imputation quality and accuracy [7] .
Concordance rate and internal quality metrics of imputation software packages are most often used to infer the extent of imputation errors. However, in comparison to these metrics, IQS is less prone to overestimating the imputation accuracy of low-frequency SNPs because IQS takes the chance agreement derived from the SNP allele frequencies into account [7] . Our study also demonstrated the advantages of using IQS as the imputation quality metric over IMPUTE2 'quality_info'.
The correction strategy eliminates all spurious associations, while the replacement strategy with IQS ≥ 0.9 eliminates most of the false-positive signals. One drawback of the replacement strategy with IQS ≥ 0.9 is that it has the risk to introduce a bias from the systematic differences to treat SNPs differently according to their IQS. This is possibly the cause of the 2 residual false positives. Both strategies increase the power of association analysis compared to the intersection strategy. We recommend the correction strategy when dealing with imputation across different genotyping arrays since it can effectively eliminate all spurious associations and provide higher statistical power than the commonly adopted intersection strategy. However, researchers should be aware of the fact that loss of power of the intersection strategy occurs for SNPs genotyped only on one array. For SNPs unavailable on any of the arrays, the two new strategies cannot improve the power to detect them. Moreover, they have little improvement on power for low-frequency and rare variants. What is more, the new strategies need to be tested genome-wide and in a larger dataset to fully gauge its powerfulness to association analysis when cases and controls are genotyped on different arrays.
